• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于同源重组缺陷相关基因鉴定肝细胞癌的分子亚型和预后特征。

Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency.

机构信息

Guangxi University of Chinese Medicine, Nanning, 530200, China.

Department of Laboratory, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.

出版信息

Sci Rep. 2021 Dec 15;11(1):24022. doi: 10.1038/s41598-021-03432-3.

DOI:10.1038/s41598-021-03432-3
PMID:34912005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8674316/
Abstract

Hepatocellular carcinoma (HCC) is a rapidly developing digestive tract carcinoma. The prognosis of patients and side effects caused by clinical treatment should be better improved. Nonnegative matrix factorization (NMF) clustering was performed using 109 homologous recombination deficiency (HRD)-related of HCC genes from The Cancer Genome Atlas (TCGA) database. Limma was applied to analyze subtype differences. Immune scores and clinical characteristics of different subtypes were compared. An HRD signature were built with least absolute shrinkage operator (LASSO) and multivariate Cox analysis. Performance of the signature system was then assessed by Kaplan-Meier curves and receiver operating characteristic (ROC) curves. We identified two molecular subtypes (C1 and C2), with C2 showing a significantly better prognosis than C1. C1 contained 3623 differentially expressed genes. A 4-gene prognostic signature for HCC was established, and showed a high predicting accuracy in validation sets, entire TCGA data set, HCCDB18 and GSE14520 queues. Moreover, the risk score was validated as an independent prognostic marker for HCC. Our research identified two molecular subtypes of HCC, and proposed a novel scoring system for evaluating the prognosis of HCC in clinical practice.

摘要

肝细胞癌 (HCC) 是一种快速发展的消化道癌。应更好地改善患者的预后和临床治疗引起的副作用。使用来自癌症基因组图谱 (TCGA) 数据库的 109 个同源重组缺陷 (HRD) 相关 HCC 基因进行非负矩阵分解 (NMF) 聚类。应用 Limma 分析亚型差异。比较不同亚型的免疫评分和临床特征。使用最小绝对值收缩和选择算子 (LASSO) 和多变量 Cox 分析构建 HRD 特征。然后通过 Kaplan-Meier 曲线和接收者操作特征 (ROC) 曲线评估特征系统的性能。我们确定了两种分子亚型 (C1 和 C2),C2 的预后明显优于 C1。C1 包含 3623 个差异表达基因。建立了 HCC 的 4 基因预后标志物,并在验证集、整个 TCGA 数据集、HCCDB18 和 GSE14520 队列中显示出较高的预测准确性。此外,风险评分被验证为 HCC 的独立预后标志物。我们的研究确定了两种 HCC 分子亚型,并提出了一种新的评分系统,用于评估 HCC 患者的临床预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/f69e8ff17c1a/41598_2021_3432_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/00e271006fe9/41598_2021_3432_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/66a084b103c5/41598_2021_3432_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/3db5cb4df4a9/41598_2021_3432_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/ef1c207efe70/41598_2021_3432_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/0b936d45926d/41598_2021_3432_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/af3d0aead286/41598_2021_3432_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/263b9c79cbf9/41598_2021_3432_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/1e579d8237a4/41598_2021_3432_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/08b6f4d7848d/41598_2021_3432_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/cbee63d33afe/41598_2021_3432_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/9c2a85600848/41598_2021_3432_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/f69e8ff17c1a/41598_2021_3432_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/00e271006fe9/41598_2021_3432_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/66a084b103c5/41598_2021_3432_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/3db5cb4df4a9/41598_2021_3432_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/ef1c207efe70/41598_2021_3432_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/0b936d45926d/41598_2021_3432_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/af3d0aead286/41598_2021_3432_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/263b9c79cbf9/41598_2021_3432_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/1e579d8237a4/41598_2021_3432_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/08b6f4d7848d/41598_2021_3432_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/cbee63d33afe/41598_2021_3432_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/9c2a85600848/41598_2021_3432_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2def/8674316/f69e8ff17c1a/41598_2021_3432_Fig12_HTML.jpg

相似文献

1
Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency.基于同源重组缺陷相关基因鉴定肝细胞癌的分子亚型和预后特征。
Sci Rep. 2021 Dec 15;11(1):24022. doi: 10.1038/s41598-021-03432-3.
2
Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.构建铁死亡相关的九个长链非编码 RNA 标志物用于预测肝细胞癌的预后和免疫反应。
Front Immunol. 2021 Sep 17;12:719175. doi: 10.3389/fimmu.2021.719175. eCollection 2021.
3
Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.基于统计与生物信息学综合分析方法构建并验证用于预测肝细胞癌患者总生存期的预后基因模型
Int J Mol Sci. 2021 Feb 5;22(4):1632. doi: 10.3390/ijms22041632.
4
Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma.七种免疫相关基因在肝癌中的预后能力及其与肿瘤浸润免疫细胞的相关性。
Cancer Med. 2020 Oct;9(20):7440-7452. doi: 10.1002/cam4.3406. Epub 2020 Aug 20.
5
Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.肿瘤浸润免疫细胞对乙型肝炎病毒相关性肝细胞癌预后预测的意义。
World J Gastroenterol. 2019 Sep 21;25(35):5266-5282. doi: 10.3748/wjg.v25.i35.5266.
6
The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.焦亡相关基因特征可预测肝细胞癌的预后,并提示免疫活性。
Mol Med. 2022 Feb 5;28(1):16. doi: 10.1186/s10020-022-00445-0.
7
TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.TANK 结合激酶 1(TBK1)通过增强肿瘤免疫浸润,可作为肝细胞癌的潜在靶点。
Front Immunol. 2021 Feb 18;12:612139. doi: 10.3389/fimmu.2021.612139. eCollection 2021.
8
Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.鉴定和描述一个 25-lncRNA 预后标志物用于预测肝细胞癌早期复发。
BMC Cancer. 2021 Oct 30;21(1):1165. doi: 10.1186/s12885-021-08827-z.
9
A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.一种新型五基因标志物可预测肝癌患者的总生存期。
Cancer Med. 2021 Jun;10(11):3808-3821. doi: 10.1002/cam4.3900. Epub 2021 May 2.
10
Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.铜死亡相关特征可预测肝细胞癌的预后、肿瘤微环境和药物敏感性。
J Immunol Res. 2022 Nov 16;2022:3393027. doi: 10.1155/2022/3393027. eCollection 2022.

引用本文的文献

1
Development and validation of a novel liquid-liquid phase separation gene signature for bladder cancer.开发和验证用于膀胱癌的新型液-液相分离基因特征。
Sci Rep. 2024 Sep 29;14(1):22552. doi: 10.1038/s41598-024-73422-8.
2
Molecular subtypes based on DNA sensors predict prognosis and tumor immunophenotype in hepatocellular carcinoma.基于 DNA 传感器的分子亚型可预测肝细胞癌的预后和肿瘤免疫表型。
Aging (Albany NY). 2023 Jul 14;15(14):6798-6821. doi: 10.18632/aging.204870.
3
Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients.

本文引用的文献

1
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.肝细胞癌的分子分型:迈向精准医学的一步。
Cancer Commun (Lond). 2020 Dec;40(12):681-693. doi: 10.1002/cac2.12115. Epub 2020 Dec 8.
2
Homologous recombination repair deficiency as a therapeutic target in sarcoma.同源重组修复缺陷作为肉瘤的治疗靶点
Semin Oncol. 2020 Dec;47(6):380-389. doi: 10.1053/j.seminoncol.2020.10.002. Epub 2020 Oct 24.
3
A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients.用于预测肝细胞癌患者复发的五基因标志物。
基于免疫相关通路、致癌通路和DNA损伤修复通路的分子亚型及IMScore用于指导肝细胞癌患者的免疫治疗
J Gastrointest Oncol. 2022 Dec;13(6):3135-3153. doi: 10.21037/jgo-22-1101.
4
Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.同源重组修复基因突变作为晚期黑色素瘤患者免疫治疗的预测性生物标志物。
Front Immunol. 2022 Aug 3;13:871756. doi: 10.3389/fimmu.2022.871756. eCollection 2022.
Biomed Res Int. 2020 Oct 24;2020:4037639. doi: 10.1155/2020/4037639. eCollection 2020.
4
DNA mismatch repair-dependent DNA damage responses and cancer.DNA 错配修复依赖性 DNA 损伤反应与癌症。
DNA Repair (Amst). 2020 Sep;93:102923. doi: 10.1016/j.dnarep.2020.102923.
5
Clinical assays for assessment of homologous recombination DNA repair deficiency.用于同源重组 DNA 修复缺陷评估的临床检测。
Gynecol Oncol. 2020 Dec;159(3):887-898. doi: 10.1016/j.ygyno.2020.09.029. Epub 2020 Oct 2.
6
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.基因组方法鉴定胰腺导管腺癌同源重组缺陷并优化治疗选择。
Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. doi: 10.1158/1078-0432.CCR-20-0418. Epub 2020 May 22.
7
Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.核干细胞通过肿瘤适应基因组应激的机制调节肝细胞癌的结局。
Mol Cancer Res. 2020 May;18(5):723-734. doi: 10.1158/1541-7786.MCR-19-0777. Epub 2020 Feb 12.
8
Immunological analyses reveal an immune subtype of uveal melanoma with a poor prognosis.免疫分析揭示葡萄膜黑色素瘤具有预后不良的免疫亚型。
Aging (Albany NY). 2020 Jan 18;12(2):1446-1464. doi: 10.18632/aging.102693.
9
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
10
Challenges in liver cancer and possible treatment approaches.肝癌的挑战与可能的治疗方法。
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314. doi: 10.1016/j.bbcan.2019.188314. Epub 2019 Nov 1.